A new era in drug research: SandboxAQ integrates scientific AI with Claude

Staff Report: PNN

Drug discovery is one of the most expensive and time-consuming areas of research in the world. Finding an effective molecule can take nearly a decade and cost billions of dollars. Even then, most research fails to produce the desired results. Although many artificial intelligence-based companies are working to reduce this complexity, the use of such technology is still largely limited to expert researchers.

Now, SandboxAQ has taken a new initiative to change this situation. The company has integrated its scientific AI model with Anthropic’s AI platform Claude. As a result, complex research and drug development technologies can now be accessed through simple conversational language.

SandboxAQ was founded about five years ago as a spin-off from Alphabet. Former Google CEO Eric Schmidt serves as its chairman. The company has already raised more than 950 million dollars from investors.

One of SandboxAQ’s most discussed technologies is the “Large Quantitative Model” or LQM. Unlike traditional language-based AI that only analyzes patterns in data, these models work based on real laws of physics and chemistry.

Through this technology, it becomes possible to simulate quantum chemistry analysis, molecular dynamics, and subtle behaviors of chemical reactions in advance. As a result, researchers can get an idea of how a potential drug or compound might behave in real life before conducting laboratory experiments.

Nadia Harhen, head of the company’s AI simulation division, said: “For the first time, advanced scientific models can now be used in natural language. Previously, special infrastructure was required to use these technologies.”

She added that SandboxAQ’s main customers include researchers, computational scientists, and experimental research teams in large pharmaceutical and industrial organizations. They use this technology to solve complex problems in developing new substances or drugs.

Experts believe that if this initiative succeeds, the use of artificial intelligence in drug research, energy, advanced materials, and financial analysis could become much easier and more widespread.